Syringe

Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retrieved on: 
Friday, December 29, 2023

Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively.

Key Points: 
  • Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively.
  • The dividends cover the period beginning October 1, 2023 through December 31, 2023.
  • The dividends will be paid on January 22, 2024 to shareholders of record as of the close of business on January 10, 2024.
  • Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle.

PetVivo Holdings, Inc. Achieves Distribution Milestone Surpassing 4500 Syringes of Spryng™ in 2023

Retrieved on: 
Thursday, December 21, 2023

MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – surpassing 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year.

Key Points: 
  • MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – surpassing 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year.
  • The distribution of syringes of Spryng is an increase in excess of sixty percent from the previous year.
  • SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
  • For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact [email protected] or visit https://petvivo.com/ and https://sprynghealth.com/ .

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Retrieved on: 
Monday, December 11, 2023

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, announced today that it plans to develop nimacimab, the Company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity. The Company has filed an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for the initiation of a Phase 2 clinical study of nimacimab in patients with obesity and chronic kidney disease.

Key Points: 
  • Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 receptor ("CB1"), which has been implicated as an important target in multiple cardiometabolic diseases including obesity and renal complications.
  • Obesity and kidney disease are highly correlated: 80% of patients who have kidney disease are also obese; 30% of obese patients have kidney disease.
  • Nimacimab effectively inhibits CB1 signaling and, based on preclinical and early clinical studies, is devoid of the CNS liabilities typically seen by small molecule drugs that target the CB1 receptor because it does not cross the blood-brain barrier.
  • Skye owns the worldwide rights to nimacimab, with patents issued in the U.S. and other territories including claims to cannabinoid 1 receptor antibodies with inverse agonist function.

No embecta-made syringes impacted by FDA safety communication

Retrieved on: 
Friday, December 1, 2023

PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes:

Key Points: 
  • PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes:
    “embecta, the world’s largest manufacturer of plastic insulin syringes, manufactures all of our syringes distributed worldwide at our facility in Holdrege, Nebraska,” said Shaun Curtis, SVP, Global Manufacturing & Supply Chain.
  • “The safety notice issued by the FDA on November 30, 2023, only applies to plastic syringes made in China, and therefore has no impact on the ongoing production or sale of any embecta syringe products.”
    “In the coming year, embecta will mark 100 years since our predecessors developed the world’s first syringe dedicated to insulin delivery, and we are proud of our rich heritage of quality, reliability, and innovation that we have earned in the years since.
  • Our skilled workforce in Nebraska, with its unmatched expertise in high volume syringe manufacturing, is prepared to support any healthcare customers who may be affected by the FDA’s safety communication.”

Multiply Labs and Akron Bio Partner to Automate the Use of cGMP-Compliant Liquid Cytokines in Cell Therapy Manufacturing

Retrieved on: 
Wednesday, December 20, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231219192070/en/
    Multiply Labs' cell therapy robotics system.
  • (Photo: Business Wire)
    Leveraging Multiply Labs' cell therapy robotic cluster, this partnership will enable Akron’s cytokines, starting with cGMP-compliant rHu Interleukin-2 (IL-2) , to be automated with the use of robotics.
  • Multiply Labs’ robotic systems will incorporate Akron’s liquid IL-2 into its cell therapy manufacturing workflow in an aseptic manner, precisely formulating and dispensing the right amount for any given process.
  • “Our partnership with Multiply Labs will allow us to integrate Akron’s cGMP materials into cell therapy manufacturing workflows - simplifying delivery and reducing risk to patients.”
    Akron and Multiply Labs will partner to integrate Akron’s existing cGMP-compliant cytokines with Multiply Labs’ proprietary adapter system, thereby making these materials compatible with Multiply Labs’ cell therapy robotic clusters.

Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals

Retrieved on: 
Thursday, December 14, 2023

Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous (IV) bag recycling program pilot.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous (IV) bag recycling program pilot.
  • View the full release here: https://www.businesswire.com/news/home/20231214638041/en/
    Photo of IV bag recycling provided by Northwestern Medicine.
  • All IV bags involved in this pilot were made of PVC, one of the most widely used plastic materials in medical products.
  • In recent years, Baxter has introduced several programs to facilitate recycling for patients and hospitals in Australia, New Zealand, Guatemala and Colombia.

Europe Syringes & Needles Insights Report 2023: A $7.97 Billion Market in 2022 - Forecasts to 2028 with BD, CardinalHealth, B Braun, Nipro, and Terumo Dominating - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023

The "Europe Syringes & Needles Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Syringes & Needles Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report delves into the intricacies of the syringes and needles market in Europe, covering the period from 2023 to 2028.
  • It provides an extensive overview of various factors that are propelling the market growth, alongside potential restraints and emerging trends.
  • Key players like BD, CardinalHealth, B Braun, Nipro, and Terumo Corp are at the forefront of the European syringes & needles market.

United States Syringes & Needles Market Insights Report 2023: A $10.87 Billion Market by 2028 with BD, ICU Medical, Nipro Medical, Terumo, and Cardinal Health Emerging as Prominent Players - ResearchAndMarkets.com

Retrieved on: 
Monday, December 11, 2023

This report offers market size & forecast data for the US syringes & needles market.

Key Points: 
  • This report offers market size & forecast data for the US syringes & needles market.
  • This report provides a comprehensive and current market scenario of the US syringes & needles market, including the US syringes & needles market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present US syringes & needles market and its market dynamics for 2023?2028.
  • BD, ICU Medical, Nipro Corporation, Terumo, and Cardinal Health are the key players in the US syringes and needles market.